Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2022
Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE TrialsUma Siangphoe, Lindsey R Baden, Hana M El Sahly, et al.
Atherosclerosis|October 1, 2013
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humansMichael H Davidson, Jason Voogt, Jayraz Luchoomun, et al.
Chemistry & Biodiversity|December 29, 2006
Identification of diverse microbial metabolites as potent inhibitors of HIV-1 Tat transactivationHiranthi Jayasuriya, Deborah L Zink, Jon D Polishook, et al.
Open Forum Infectious Diseases|December 16, 2024
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE TrialDean Follmann, Xiaowei Wang, Lindsey R Baden, et al.
The Journal of Infectious Diseases|February 13, 2024
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing VaccinesSpyros Chalkias, Nichole McGhee, Jordan L Whatley, et al.
Nature Communications|August 23, 2023
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The New England Journal of Medicine|September 16, 2022
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The Journal of Biological Chemistry|January 30, 2003
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogsSteven S Carroll, Joanne E Tomassini, Michele Bosserman, et al.
Nature Medicine|February 11, 2022
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trialRolando Pajon, Yamuna D Paila, Bethany Girard, et al.
The Lancet. Infectious Diseases|November 28, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trialJaya Goswami, Jose F Cardona, Denise C Hsu, et al.
Pageof 16